Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 86

Sort by

Sort Order Select

Journal Articles

Optimal infection prophylaxis strategy for relapsed/refractory multiple myeloma patients undergoing elranatamab therapy (OPTIMUS-EL)

Ja Min Byun, Dong Hyun Kim, Youngil Koh, Chang-Ki Min, Kihyun Kim, Hee Jeong Cho, Ji Yun Lee

Blood (2025) 146 (Supplement 1): 8237.

https://doi.org/10.1182/blood-2025-8237

Published: 2025

Journal Articles

Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study

Blood (2025) 146 (Supplement 1): 5840.

https://doi.org/10.1182/blood-2025-5840

Published: 2025

Journal Articles

Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 1

Ja Min Byun, Chang-Ki Min, Kihyun Kim, Dok Hyun Yoon, Sung-Hoon Jung, Wee-Joo Chng, Chandramouli Nagarajan, Youngil Koh

Blood (2025) 146 (Supplement 1): 5835.

https://doi.org/10.1182/blood-2025-5835

Published: 2025

Journal Articles

Phase 1 study of GCC2005, an allogeneic CD5-directed CAR-NK therapy, for patients with Relapsed/Refractory NK/T-cell malignancies

Won-Seog Kim, Dok Hyun Yoon, Youngil Koh, Seok Jin Kim, Sang Eun Yoon, Hyungwoo Cho, Jaewon Hyung, Ja Min Byun, Hyesung Jeon, Seungryel Han

Blood (2025) 146 (Supplement 1): 1043.

https://doi.org/10.1182/blood-2025-1043

Published: 2025

Journal Articles

Phase II study of lenalidomide in combination with rituximab, cyclophosphadmie, doxorubicin, vincristine, and prenisone (R-CHOP) for central nervous system prophylaxis in high-risk diffuse large B cell lymphoma

Hyungwoo Cho, Jaewon Hyung, Hyeon-Seok Eom, Sung-Nam Lim, Hye Jin Kang, Myung-Won Lee, Young Rok Do, Seong Hyun Jeong, Hyo Jung Kim, Youngil Koh, Seong Yoon Yi, Ka-Won Kang, Min Kyoung Kim, Jae-Yong Kwak, Gyeong-Won Lee, Dok Hyun Yoon

Blood (2025) 146 (Supplement 1): 1915.

https://doi.org/10.1182/blood-2025-1915

Published: 2025

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

Blood (2025) 146 (Supplement 1): 665.

https://doi.org/10.1182/blood-2025-665

Published: 2025

Journal Articles

Old mismatched donors are associated with inferior outcomes after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndrome, but not in Acute Myeloid Leukemia

Dong Hyun Kim, Ja Min Byun, Dong-Yeop Shin, Youngil Koh, Inho Kim, Sung-Soo Yoon, Hyo Jung Kim, Junglim Lee, Junshik Hong

Blood (2025) 146 (Supplement 1): 6052.

https://doi.org/10.1182/blood-2025-6052

Published: 2025

Journal Articles

Study design of A phase 3, open-label trial for pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria with inadequate control of intravascular hemolysis

Blood (2025) 146 (Supplement 1): 4988.

https://doi.org/10.1182/blood-2025-4988

Published: 2025

Journal Articles

Updated clinical data and biomarker analyses from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with relapsed/refractory cytotoxic lymphomas

Blood (2025) 146 (Supplement 1): 3646.

https://doi.org/10.1182/blood-2025-3646

Published: 2025

Journal Articles

Trial in progress: A Phase 2a Study of GI-102 (CD80/IL2v3) as a consolidation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma following anti-CD19 chimeric antigen receptor T-cell therapy (CARNATION trial)

Dok Hyun Yoon, Hyungwoo Cho, Jaewon Hyung, Yoon Seok Choi, Youngwoo Jeon, Seok Jin Kim, Youngil Koh, Nari Yun, Woohyung Lee, Chanmi Kim, Myoung Ho Jang

Blood (2025) 146 (Supplement 1): 2399.

https://doi.org/10.1182/blood-2025-2399

Published: 2025

Journal Articles

Poseltinib combined with rituximab and lenalidomide is a promising chemotherapy-free therapy in relapsed or refractory primary central nervous system lymphoma

Dong Hyun Kim, Sanyeowool An, Ka-Won Kang, Sang Eun Yoon, Seok Jin Kim, Hyo Jung Kim, Youngil Koh, Deok-Hwan Yang

Blood (2025) 146 (Supplement 1): 3692.

https://doi.org/10.1182/blood-2025-3692

Published: 2025

Journal Articles

Artificial intelligence (AI)–based membrane specific PD-L1 and immune subtypes as predictive biomarkers for danburstotug in relapsed or refractory extranodal NK/T cell lymphoma (R/R ENKTL): Insights from the Phase II trial (DISTINKT)

Won Seog Kim, Seok Jin Kim, Jae-Cheol Cho, Sang Eun Yoon, Youngil Koh, Deok-Hwan Yang, Dok Hyun Yoon, Junhun Cho, Sung Young Lee, Seongyeon Kang, Woochan Hwang, Hyukjung Kim, Heung Tae Kim

Blood (2025) 146 (Supplement 1): 5426.

https://doi.org/10.1182/blood-2025-5426

Published: 2025

Journal Articles

NB02 (Poseltinib) combined rituximab and lenalidomide in R/ R PCNSL (POTENTIAL-P): Initial results of safety lead-in cohort.

Deok-Hwan Yang, Sung Yong Oh, Youngwoo Jeon, Ga-Young Song, Seokjin Kim, Sang Eun Yoon, Tong-Yoon Kim, Ji Hyun Lee, Hye Ryeon Kim, Youngil Koh, Han Song, Myungsea Lee, Won Seog Kim

Blood (2025) 146 (Supplement 1): 5463.

https://doi.org/10.1182/blood-2025-5463

Published: 2025

Journal Articles

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

Blood (2025) 146 (Supplement 1): 226.

https://doi.org/10.1182/blood-2025-226

Published: 2025

Journal Articles

Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry

Blood (2024) 144 (Supplement 1): 1636.

https://doi.org/10.1182/blood-2024-202823

Published: 2024

Journal Articles

ATR Inhibitor Elimusertib Suppresses Drug Persister Clones in TP53 -Mutated Acute Myeloid Leukemia Via CGAS-Sting-Mediated Cell Death

Dongchan Kim, Daehyeon Gwak, Ja Min Byun, Youngil Koh, Junshik Hong, Jung Lim Lee, Sung-Soo Yoon, Dong-Yeop Shin

Blood (2024) 144 (Supplement 1): 1375.

https://doi.org/10.1182/blood-2024-202733

Published: 2024

Journal Articles

Spectrum of TP53 Mutation in Hematologic Malignancies

Seo Yoon Jang, Joowon Jang, Jee-Soo Lee, Songyi Park, Ja Min Byun, Youngil Koh, Junshik Hong, Inho Kim, Sung-Soo Yoon, Dong-Yeop Shin

Blood (2024) 144 (Supplement 1): 5731.

https://doi.org/10.1182/blood-2024-210051

Published: 2024

Journal Articles

Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis

Blood (2024) 144 (Supplement 1): 497.

https://doi.org/10.1182/blood-2024-198669

Published: 2024

Journal Articles

Efficacy and Safety of T-Cell Engagers Compared to Standard of Care for Relapsed/Refractory Multiple Myeloma Treatment: A Real-World RCT Mimicking Analyses

Ja Min Byun, Sung-Soo Park, Suein Choi, Youngil Koh, Chang-Ki Min, Seunghoon Han

Blood (2024) 144 (Supplement 1): 4707.

https://doi.org/10.1182/blood-2024-198337

Published: 2024

Journal Articles

Unraveling TP53 -Mutated Acute Myeloid Leukemia : Clinical Insights and Genetic Profiles

Songyi Park, Sang-A Kim, Ji Yun Lee, Ja Min Byun, Jeong-Ok Lee, Youngil Koh, Junshik Hong, Junglim Lee, Soo-Mee Bang, Inho Kim, Sung-Soo Yoon, Dongyeop Shin

Blood (2024) 144 (Supplement 1): 5944.

https://doi.org/10.1182/blood-2024-202293

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Optimal infection prophylaxis strategy for relapsed/refractory multiple myeloma patients undergoing elranatamab therapy (OPTIMUS-EL)

Belantamab mafodotin (belamaf) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) for patients (pts) with transplant-ineligible (TI) newly diagnosed multiple myeloma (NDMM): A focus on treatment efficacy and management/resolution of ocular events in the Phase 1 dreamm-9 study

Phase I/II study of mezigdomide and elranatamab for relapsed/refractory multiple myeloma patients (MELT-MM): Initial results from part 1

Phase 1 study of GCC2005, an allogeneic CD5-directed CAR-NK therapy, for patients with Relapsed/Refractory NK/T-cell malignancies

Phase II study of lenalidomide in combination with rituximab, cyclophosphadmie, doxorubicin, vincristine, and prenisone (R-CHOP) for central nervous system prophylaxis in high-risk diffuse large B cell lymphoma

Pirtobrutinib in Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Final update from the Phase 1/2 BRUIN study

Old mismatched donors are associated with inferior outcomes after allogeneic hematopoietic stem cell transplantation in myelodysplastic syndrome, but not in Acute Myeloid Leukemia

Study design of A phase 3, open-label trial for pozelimab and cemdisiran combination therapy in patients with paroxysmal nocturnal hemoglobinuria with inadequate control of intravascular hemolysis

Updated clinical data and biomarker analyses from the phase 1 study of DR-01, a non-fucosylated anti-CD94 antibody in patients with relapsed/refractory cytotoxic lymphomas

Trial in progress: A Phase 2a Study of GI-102 (CD80/IL2v3) as a consolidation therapy in patients with relapsed/refractory diffuse large B-cell lymphoma following anti-CD19 chimeric antigen receptor T-cell therapy (CARNATION trial)

Poseltinib combined with rituximab and lenalidomide is a promising chemotherapy-free therapy in relapsed or refractory primary central nervous system lymphoma

Artificial intelligence (AI)–based membrane specific PD-L1 and immune subtypes as predictive biomarkers for danburstotug in relapsed or refractory extranodal NK/T cell lymphoma (R/R ENKTL): Insights from the Phase II trial (DISTINKT)

NB02 (Poseltinib) combined rituximab and lenalidomide in R/ R PCNSL (POTENTIAL-P): Initial results of safety lead-in cohort.

Pirtobrutinib in Relapsed/Refractory (R/R) Waldenström macroglobulinemia (WM): Up to 5 years of follow-up from the Phase 1/2 BRUIN study

Sequential Bruton Tyrosine Kinase Inhibitor Therapy in Relapsed or Refractory Mantle Cell Lymphoma Following Chemotherapy: Real-World Outcomes and Attrition Rates - an Updated Report from the Asia-Pacific Multinational Retrospective Registry

ATR Inhibitor Elimusertib Suppresses Drug Persister Clones in TP53 -Mutated Acute Myeloid Leukemia Via CGAS-Sting-Mediated Cell Death

Spectrum of TP53 Mutation in Hematologic Malignancies

Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis

Efficacy and Safety of T-Cell Engagers Compared to Standard of Care for Relapsed/Refractory Multiple Myeloma Treatment: A Real-World RCT Mimicking Analyses

Unraveling TP53 -Mutated Acute Myeloid Leukemia : Clinical Insights and Genetic Profiles

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only